Related Experiment Video
Updated: Mar 17, 2026
In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model
Published on: October 3, 2011
Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor
Rajesh Kumar1, Eun-Joong Kim2, Jiyou Han3
1Department of Chemistry, Korea University, Seoul 02841, Republic of Korea.
Abstract:
Hypoxia, a distinguished feature of various solid tumors, has been considered as a key marker for tumor progression. Inadequate vasculature and high interstitial pressures result in relatively poor drug delivery to these tumors. Herein, we developed an antitumor theranostic agent, 4, which is activated in hypoxic conditions and can be used for the diagnosis and treatment of solid tumors. Compound 4, bearing biotin, a tumor-targeting unit, and SN38, an anticancer drug, proved to be an effective theranostic agent for solid tumors. SN38 plays a dual role: as an anticancer drug for therapy and as a fluorophore for diagnosis, thus avoids an extra fluorophore and limits cytotoxicity. Compound 4, activated in the hypoxic environment, showed high therapeutic activity in A549 and HeLa cells and spheroids. In vivo imaging of solid tumors confirmed the tumor-specific localization, deep tissue penetration and activation of compound 4, as well as the production of a strong anticancer effect through the inhibition of tumor growth in a xenograft mouse model validating it as a promising strategy for the treatment of solid tumors.
Insights
Researchers developed a novel theranostic agent activated by tumor hypoxia. This agent targets tumors, enabling simultaneous diagnosis and treatment, demonstrating significant antitumor effects in preclinical models.
Area of Science:
- Biomedical Engineering
- Oncology
- Drug Delivery
Background:
- Hypoxia is a hallmark of solid tumors, impeding drug delivery and promoting progression.
- Poor drug penetration in tumors necessitates innovative therapeutic strategies.
Purpose of the Study:
- To develop a hypoxia-activated theranostic agent for solid tumors.
- To combine tumor targeting, diagnosis, and therapy into a single agent.
Main Methods:
- Synthesis of a theranostic agent (Compound 4) incorporating biotin for targeting and SN38 for therapy/diagnosis.
- In vitro evaluation in A549 and HeLa cells and spheroids under hypoxic conditions.
- In vivo studies using a xenograft mouse model for imaging and therapeutic efficacy assessment.
Main Results:
- Compound 4 demonstrated hypoxia-specific activation and potent antitumor activity.
- In vivo imaging confirmed tumor-specific localization and deep tissue penetration.
- Significant inhibition of tumor growth was observed in the xenograft model.
Conclusions:
- Compound 4 is an effective hypoxia-activated theranostic agent for solid tumors.
- The dual role of SN38 as a drug and fluorophore simplifies the theranostic system.
- This strategy shows promise for improved cancer diagnosis and treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies